Secondary Logo

Journal Logo

Original Article

Prostaglandin E2 induction of labor and cervical ripening for term isolated oligohydramnios in pregnant women with Bishop score ≤ 5

Kansu-Celik, Hatice*; Gun-Eryılmaz, Ozlem; Dogan, Nasuh Utku; Haktankaçmaz, Seval; Cinar, Mehmet; Yilmaz, Saynur Sarici; Gülerman, Cavidan

Author Information
Journal of the Chinese Medical Association: March 2017 - Volume 80 - Issue 3 - p 169-172
doi: 10.1016/j.jcma.2016.07.004


    1. Introduction

    Oligohydramnios complicates 0.5–5% of all pregnancies. The prevalence of oligohydramnios depends largely on the definition and criteria used for distinguishing it from others.1 The common etiological factors associated with oligohydramnios are ruptured membranes, congenital abnormalities, and placental insufficiency. It is thought to be associated with increased maternal and fetal morbidities. The perinatal morbidity and mortality are due to a high risk of caesarean deliveries owing to fetal distress, low Apgar scores, and meconium aspiration syndrome in the fetus.2

    Fluid volume is a biophysical parameter with particular significance in high-risk pregnancies, as it provides valuable information about fetal well-being and for decision-making for induction of labor. Because oligohydramnios has been circumstantially associated with a variety of poor pregnancy outcomes, obstetricians have increasingly resorted to induction of labor in pregnancies complicated by decreased amniotic fluid volume.3

    The ideal method to induce labor should be safe, painless, inexpensive, comfortable, and effective. However, such a perfect method does not exist at present. Most of the currently available methods for labor induction try to mimic the physiological sequence of cervical effacement and dilatation followed by uterine contraction, but the majority achieve only part of the natural progression. Oxytocin, misoprostol, and dinoprostone are the most often used agents for cervical ripening and labor induction.4

    In this study, we aimed to compare the efficacy and safety of dinoprostone for cervical ripening and labor induction in term pregnancies with isolated oligohydriamnios.

    2. Methods

    This prospective study was conducted at the Zekai Tahir Burak Woman's Health, Research and Education Hospital, Ankara, Turkey between April 2009 and August 2009. The study was approved by the local Ethics Committee of the hospital, and an informed consent was signed by all patients before treatment, as in all cases of labor induction at our institution. Forty consecutive women with term isolated oligohydramnios and Bishop score≤5 underwent induction of labor with a vaginal insert containing 10-mg timed-release dinoprostone (prostaglandin E2; Group A). Oligohydramnios was defined as an amniotic fluid index (AFI) of < 5 cm.2 The control group, Group B, consisted of 64 cases of pregnancy with normal amniotic fluid volume (AFI ≥ 5 cm) and Bishop score≤5, and was matched for patient's age and parity. The criteria of inclusion were women with a singleton live cephalic presentation between 37 weeks and 42 weeks, intact amniotic membranes, and reassuring fetal heart rate (FHR). The exclusion criteria were multifetal gestation; noncephalic presentation; premature rupture of membranes; suspicious or ominous nonstress test result at admission; placenta previa; suspected macrosomia over 4000 g; a history of uterine scarring or pregnancies complicated by evidence of fetal congenital malformations, gestational diabetes, hypertension, intrauterin growth retardation, or chronic illness; and any other contraindication to vaginal delivery. Patients with contraindication to prostaglandins administration (allergy, severe asthma, or pre-existing cardiac or cardiovascular disease), renal or hepatic dysfunction, and parity > 5 were also excluded. None of the women in the study received epidural or other modes of analgesia.

    Gestational age was established by the last reported menstrual period and first-trimester ultrasound measurements. Ultrasonography was performed on all patients to assess presentation of fetus, estimated fetal weight, placental site, and amniotic fluid volume. The amniotic fluid volume was estimated according to the four-quadrant technique.5 The uterus was divided into four quadrants, by the umbilicus transversely (into upper and lower halves) and by the linea nigra (into right and left halves). The maximum vertical diameter of the largest pocket in each quadrant without an aggregate of cord or fetal extremities was measured in centimeters. The sum of the largest vertical pocket in the four quadrants was the AFI. A depth of 0–5 equated with oligohydramnios.

    The dinoprostone insert was left in situ for 12 hours, if possible, or removed at the onset of active labor. Active labor was considered to begin when cervical dilatation was 4 cm.6 All cases were followed by continuous electronic fetal monitoring. A partogram was drawn to follow the progress of labor. Artificial rupture of membranes was done at 5-cm dilatation, and color of amniotic fluid (liquor amnii) was noted. At the 12th hour from the start of treatment, the Bishop scores were re-evaluated. For patients whose Bishop score was still<5 (i.e., not exhibiting regular uterine contraction), a vaginal application of dinoprostone was performed and they were induced with low-dose oxytocin infusion. Oxytocin augmentation was applied in the second stage, if necessary.

    Tachysystole was defined as six or more than five contractions in 10 minutes, averaged over a 30-minute window. Hyperstimulation was described as a tachysystole with late FHR decelerations or fetal tachycardia (> 160 beats/min) or other worrying FHR changes.7 In the event of hyperstimulation, the vaginal dinoprostone insert was removed, and fetal resuscitation (and tocolysis, if needed) was done. Non-reassuring FHR patterns were defined as persistent or recurring episodes of severe variable decelerations, late decelerations, prolonged fetal bradycardia, or a combination of decreased beat-to-beat variability and a decelerative pattern.

    Demographic and antenatal data were collected from the delivery chart, computerized data, and patient files. The primary outcome measures were time from induction to delivery and incidence of vaginal delivery; the secondary outcomes were the caesarean section (CS) rate, side effects, rate of failed induction, the incidence of admission to the neonatal intensive care unit, and neonatal complications.

    All statistical analyses were performed using SPSS software (version 15; SPSS Inc., Chicago, IL, USA). Continuous data are expressed as mean (standard deviation) and were analyzed with two independent-samples tests. Chi-square and Fisher's exact tests were used for categorical data. The significance boundary (p) was given as 0.05.

    3. Results

    A total of 148 patients who satisfied the trial criteria were recruited into the study; of these, 44 patients declined to participate, and thus 104 patients [patients with oligohydramnios (n=40) and control patients (n=64)] completed the study (Fig. 1). The demographic variables of the patients in Groups A and B are presented in Table 1; age, parity, and Bishop scores were insignificant between the groups (p>0.05 for all). Gestational age was significantly different between the groups (p=0.001).

    Table 1
    Table 1:
    Demographic characteristics.
    Fig. 1
    Fig. 1:
    Flowchart of study profile.

    Table 2 summarizes the obstetric and neonatal outcomes. The mean time intervals from induction to delivery were 21.76±4.49 hours and 20.86±4.04 hours for the oligohydramnios and control groups, respectively (p>0.05). CS rate was significantly different between the groups, 40.0% and 15.6% for the oligohydramnios and the control groups, respectively (p=0.005). Hyperstimulation occurred in four of 40 patients in the oligohydramnios group and in one of 64 patients in the control group, without reaching statistically significant difference.

    Table 2
    Table 2:
    Cervical ripening, labor, delivery, and neonatal outcomes of patients.

    Of the patients in Groups A and B, 7.5% (3/40) and 3.1% (2/64), respectively, needed admission to neonatal intensive care unit within 24 hours after delivery (p>0.05). There was no statistically significant difference in the 5th-minute Apgar score and postpartum hemorrhage between the groups (p>0.05). There were no uterine ruptures, infectious complications, or other major maternal complications.

    4. Discussion

    Our study regarding the efficacy and safety of dinoprostone for cervical ripening and labor induction in term pregnancies with a Bishop score≤5 between patients with isolated oligohydramnios and normal amniotic fluid revealed that dinoprostone did not decrease the mean time interval from induction to delivery. In addition to these results, the rate of CS in patients with oligohydramnios was higher than in those with normal amniotic fluid.

    Induction of labor is a widely used procedure for various maternal and fetal indications, one of which is oligohydramnios. In many cases, the cervix may not be ripened enough, especially in primigravidas. Therefore, there is a need to prepare the cervix for a likely vaginal birth. Various techniques have been used for this purpose, with vaginal dinoprostone administration being one of the most commonly used methods of all.8 In this prospective study, dinoprostone administered by the standard once-daily regimen demonstrated a significantly higher rate of labor success within 24 hours in the oligohydramnios and control groups (72% vs. 78%), and the rate of oxytocin use was similar in both groups. Venturini et al9 and Stefos et al10 studied dinoprostone gel action vaginally and concluded that it was noneffective in lessening the duration of labor. The primary outcomes of our study also supported the previous results.

    Classically, oligohydramnios has been related to increased neonatal mortality and morbidity in high-risk pregnancy status.11 However, some investigators have found an association between an active induction of labor in term low-risk pregnancy with isolated oligohydramnios and an increased rate of cesarean section without causing any detrimental neonatal outcomes, when compared with normal AFI.12–16 A meta-analysis done by Chauchan et al17indicated that there was no association between olygohydramnios and neonatal acidosis, even though acidosis resulted in AFI<5 with an increased risk of CS due to fetal distress and lower Apgar score. However, this analysis involved high-risk and preterm pregnancies. Some retrospective studies of term pregnancies with isolated oligohydramnios reported no differences in Apgar score, requirement of neonatal intensive care unit, fetal acidosis, or perinatal death from normal AFI pregnancies with induction of labor.12,18,19 Similarly, we also found an increased rate of cesarean section in patients with oligohydramnios without an increase in adverse perinatal outcomes. By contrast, in a retrospective study by Danon et al,20 patients with uncomplicated oligohydramnios at term underwent induction of labor with prostaglandin E2; the investigators concluded that the induction of labor for oligohydramnios was an overtreatment, and proposed close surveillance to lower the rate of CS.

    Dinoprostone has been administered either vaginally or intracervically, rather successfully and without serious side effects in normal pregnancies.13 The most important adverse reaction of dinoprostone is uterine hyperstimulation. The incidence of uterine hyperstimulation ranged from 5% to 16% in patients treated with controlled-release dinoprostone.21 This condition generally resolves within 15 minutes after removal of the insert, and patients experiencing hyperstimulation gave birth to healthy babies without requiring a CS. Cardiotocogrophic abnormalities are monitored in 3–10% of women receiving dinoprostone; most of these abnormalities also resolve quickly after insert removal.21 With regard to dinoprostone administration and uterine hyperstimulation frequency, results of our study are similar to others.

    In conclusion, a single dose (10 mg) of controlled-release dinoprostone administered vaginally appears to be a safe for induction of labor in patients with oligohydramnios. Increased rates of CS is the detrimental effect of dinoprostone but it does not have a negative impact on neonatal outcomes. Prospective, randomized controlled clinical trials with large numbers of patients are needed to compare dinoprostone in term pregnancies with isolated oligohydramnios.


    1. Hill LM, Breckle R, Wolfgram KR, O’Brien PC. Oligohydramnios: ultrasonically detected incidence and subsequent fetal outcome. Am J Obstet Gynecol. 1983;147:407-410.
    2. McCurdy CM Jr, Seeds JW. Oligohydramnios: problems and treatment. Semin Perinatol. 1993;17:183-196.
    3. Morris RK, Meller CH, Tamblyn J, Malin GM, Riley RD, Kilby MD, et al. Association and prediction of amniotic fluid measurements for adverse pregnancy outcome: systematic review and meta-analysis. BJOG. 2014;121:686-699.
    4. Tenore JL. Methods for cervical ripening and induction of labor. Am Fam Physician. 2003;67:2123-2128.
    5. Shanks A, Tuuli M, Schaecher C, Odibo AO, Rampersad RJ. Assessing the optimal definition of oligohydramnios associated with adverse neonatal outcomes. J Ultrasound Med. 2011;30:303-307.
    6. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap LC, Wenstrom KD. 2005. Williams obstetrics, 22nd ed. McGraw-Hill, New York.
    7. ACOG Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol. 2009;114:386-397.
    8. Keirse MJ. Prostaglandins in preinduction cervical ripening. Meta-analysis of worldwide clinical experience. J Reprod Med. 1993;38:89-100.
    9. Venturini P, Contu G, Mazza V, Facchinetti F. Induction of labor in women with oligohydramnios. J Matern Fetal Neonatal Med. 2005;17:129-132.
    10. Stefos T, Mouzakioti E, Sotiriadis A, Andronikou S, Adamidis K, Lolis D. Use of prostaglandin E2 for cervical ripening in pregnancies with oligohydramnios. Gynecol Obstet Invest. 2000;50:158-161.
    11. Sowmya K, Varghese B, Umashankar BY. Effect of isolated oligohydramnios in otherwise normal term pregnancy. Int J Biomed Res. 2014;5:98-101.
    12. Zhang J, Troendle J, Meikle S, Klebanoff MA, Rayburn WF. Isolated oligohydramnios is not associated with adverse perinatal outcomes. BJOG. 2004;111:220-225.
    13. Smith CV, Rayburn WF, Miller AM. Intravaginal prostaglandin E2 for cervical ripening and initiation of labor. Comparison of a multidose gel and single, controlled-release pessary. J Reprod Med. 1994;39:381-384.
    14. Zanini A, Ghidini A, Norchi S, Beretta E, Cortinovis I, Bottino S. Pre-induction cervical ripening with prostaglandin E2 gel: intracervical versus intravaginal route. Obstet Gynecol. 1990;76:681-683.
    15. Stempel JE, Prins RP, Dean S. Preinduction cervical ripening: a randomized prospective comparison of the efficacy and safety of intravaginal and intracervical prostaglandin E2 gel. Am J Obstet Gynecol. 1997;176:1305-1309.
    16. Conway DL, Adkins WB, Schroeder B, Langer O. Isolated oligohydramnios in the term pregnancy: is it a clinical entity? J Matern Fetal Med. 1998;7:197-200.
    17. Locatelli A, Vergani P, Toso L, Verderio M, Pezzullo JC, Ghidini A. Perinatal outcome associated with oligohydramnios in uncomplicated term pregnancies. Arch Gynecol Obstet. 2004;269:130-133.
    18. Voxman EG, Tran S, Wing DA. Low amniotic fluid index as a predictor of adverse perinatal outcome. J Perinatol. 2002;22:282-285.
    19. Rainford M, Adair R, Scialli AR, Ghidini A, Spong CY. Amniotic fluid index in the uncomplicated term pregnancy. Prediction of outcome. J Reprod Med. 2001;46:589-592.
    20. Danon D, Ben-Haroush A, Yogev Y, Bar J, Hod M, Pardo J. Prostaglandin E2 induction of labor for isolated oligohydramnios in women with unfavorable cervix at term. Fetal Diagn Ther. 2007;22:75-79.
    21. Rath W. A clinical evaluation of controlled-release dinoprostone for cervical ripening—a review of current evidence in hospital and outpatient settings. J Perinat Med. 2005;33:491-499.

    caesarean section rate; cervical ripening; dinoprostone; induction of labor; oligohydramnios

    © 2017 by Lippincott Williams & Wilkins, Inc.